Homeostatic plasticity is characterized by compensatory changes in synaptic strength and intrinsic membrane properties in response to chronic changes in neuronal activity. Neonatal seizures are a naturally occurring source of neuronal overactivation and can lead to long-term epilepsy and cognitive deficits. Using a rodent model of hypoxiainduced neonatal seizures that results in a persistent increase in AMPA receptor (AMPAR) function in hippocampal CA1 pyramidal neurons, we aimed to determine whether there was any evidence of an opposing endogenous homeostatic antiepileptic response. Given that this model results in long-term epilepsy, we also examined mechanisms whereby this homeostasis fails. Whole-cell patch-clamp recordings from neurons in slices removed at intervals following seizure onset revealed an initial up-regulation of AMPAR function that was followed by a transient dynamic attenuation of this enhancement by 48-72 h, although AMPAR function was still increased compared with nonseizure control baseline. This secondary down-regulation of enhanced AMPAR function was coincident with a marked transient increase in expression and function of the Polo-like kinase 2 (PLK2), which has previously been implicated in homeostatic down-regulation of neuronal excitability in cell/slice culture models. The effects were transient and at 1 wk AMPAR function once again became up-regulated, simultaneous with a decrease in PLK2 expression and function. This negative regulation was mediated by subacute postseizure increases in mammalian target of rapamycin (mTOR). Application of the mTOR inhibitor rapamycin prevented post-hypoxic seizure impairment of homeostasis, suggesting that homeostatic plasticity mechanisms may be potentially modifiable therapeutic targets in epileptogenesis.
Homeostatic plasticity is characterized by compensatory changes in synaptic strength and intrinsic membrane properties in response to chronic changes in neuronal activity. Neonatal seizures are a naturally occurring source of neuronal overactivation and can lead to long-term epilepsy and cognitive deficits. Using a rodent model of hypoxiainduced neonatal seizures that results in a persistent increase in AMPA receptor (AMPAR) function in hippocampal CA1 pyramidal neurons, we aimed to determine whether there was any evidence of an opposing endogenous homeostatic antiepileptic response. Given that this model results in long-term epilepsy, we also examined mechanisms whereby this homeostasis fails. Whole-cell patch-clamp recordings from neurons in slices removed at intervals following seizure onset revealed an initial up-regulation of AMPAR function that was followed by a transient dynamic attenuation of this enhancement by 48-72 h, although AMPAR function was still increased compared with nonseizure control baseline. This secondary down-regulation of enhanced AMPAR function was coincident with a marked transient increase in expression and function of the Polo-like kinase 2 (PLK2), which has previously been implicated in homeostatic down-regulation of neuronal excitability in cell/slice culture models. The effects were transient and at 1 wk AMPAR function once again became up-regulated, simultaneous with a decrease in PLK2 expression and function. This negative regulation was mediated by subacute postseizure increases in mammalian target of rapamycin (mTOR). Application of the mTOR inhibitor rapamycin prevented post-hypoxic seizure impairment of homeostasis, suggesting that homeostatic plasticity mechanisms may be potentially modifiable therapeutic targets in epileptogenesis. immature brain | development E pilepsy is one of the most prevalent neurological disorders, affecting ∼1-2% of the United States population (1) . The neonatal period is one of the highest incidence periods for seizures across the lifespan, with hypoxic encephalopathy being the most common cause (2, 3) . Neonatal seizures are often refractory to conventional antiepileptic drugs and can result in chronic laterlife epilepsy and long-term behavioral and cognitive deficits (4, 5) .
Using an established neonatal hypoxic seizure (HS) model in rats, we previously showed neonatal HS results in both acute and long-term enhancement in hippocampal and cortical excitability and later-life epilepsy (6) (7) (8) . We have demonstrated a critical role for seizure-induced early posttranslational modifications of the AMPA receptors (AMPAR) to enhance synaptic excitability (3, 6, 7, 9) , and a dependence upon activation of the mammalian target of rapamycin (mTOR) pathway (9) .
Neonatal seizure-induced increases in AMPAR function involve mechanisms of receptor trafficking implicated in Hebbian synaptic plasticity (6, 10) . Although Hebbian synaptic plasticity is robust in the developing brain at baseline and after seizures, relatively few studies have focused on the status of homeostatic plasticity in the developing brain (11, 12) . Homeostatic synaptic plasticity provides neurons with ability to maintain their activity within normal functional boundaries through globally scaling up or down of synaptic strength in response to chronic activity changes (13) (14) (15) . Homeostatic plasticity (i.e., scaling up) could lower seizure threshold, and can be seen after tetrodotoxin-induced activity silencing in hippocampal slice cultures (16, 17) and by traumatic brain injury-induced decreases in neuron functional activity (18, 19) . On the other hand, homeostatic plasticity (i.e., synaptic scaling down) could represent an endogenous antiepileptic response to the naturally occurring neuronal overactivation during seizures.
The molecular mechanisms of homeostatic plasticity are likely to be multifactorial. The Polo-like kinase 2 (PLK2) belongs to the family of serine/threonine kinases involved in cell-cycle progression (20, 21) . PLK2 is also critically involved in down-regulation of synaptic strength in response to prolonged increases in neuronal activity (22) . Active PLK2 promotes the phosphorylation and degradation of SPAR, a postsynaptic Rap GAP (GTPase-activating protein) and PSD95, and thus mediates compensatory effects through down-regulating AMPAR function in response to elevated activity in vitro (22) (23) (24) . Here we hypothesized that, in addition to previously documented Hebbian increases in synaptic function (7), PLK2-mediated homeostatic plasticity may provide endogenous protection against HS-induced neural overactivation in immature brain in vivo.
We report here the parallel time course of seizure-induced changes in PLK2 expression with homeostatic compensation of AMPAR function in CA1 pyramidal neurons in slices removed at intervals up to 20 d after in vivo HS in postnatal day (P) 10 rats. Given that we found homeostatic compensation was only transient and incomplete, we further examined potential mechanisms for this failure to correct seizure-induced increases in AMPAR function. Consistent with our prior report of HS-induced activation of the mTORC1 pathway (9), we report here that mTORC1 inhibition can promote PLK2 expression and homeostatic stabilization of neural network excitability. In summary, these results identify a unique and potentially regulatable homeostatic plasticity mechanism that occurs following seizures in the neonatal brain.
Results
Homeostatic Down-Modulation of Seizure-Induced Enhancement in AMPAR Function. To test whether early life HS would induce homeostatic changes in AMPAR function in hippocampal CA1 pyramidal neurons, we performed whole-cell voltage-clamp recordings in post-HS rat pups immediately after HS at P10 and up to 20 d after the initial insult, as well as in littermate controls. In agreement with previous studies (6, 7), slices from post-HS rats at 1-3 h time points showed significant increases in both amplitude and frequency of AMPAR-mediated spontaneous excitatory postsynaptic currents (AMPAR sEPSCs) compared with littermate normoxic controls (amplitude: 178.94 ± 7.85% of control, P < 0.001, n = 12; frequency: 433.19 ± 50.79% of control, P < 0.01, n = 12) (Fig. 1) . At 12 h postseizure, the amplitude and frequency of AMPAR sEPSCs were still significantly elevated compared with littermate normoxic controls (post-HS 12 h: amplitude 162.75 ± 7.03% of control, P < 0.001, n = 9; frequency: 273.56 ± 39.34% of control, P < 0.05, n = 9). However, following this acute period of 1-12 h, there was a secondary phase of gradually decreasing up to 72 h after HS (post-HS 24 h: amplitude 137.68 ± 5.63% of control, n = 9, P < 0.01; frequency 197.23 ± 28.40% of control, n = 9 P < 0.05; post-HS 48-72 h: amplitude 130.77 ± 6.19% of control, n = 8, P < 0.01; frequency 195.54 ± 37.33% of control, n = 8), although at all times the AMPAR sEPSC amplitude and frequency remained persistently above control baseline. AMPAR sEPSC frequency and amplitude then once again gradually increased at post-HS 12-13 d (post-HS 5-7 d: amplitude 132.52 ± 5.69% of control, P < 0.01, n = 7; frequency 211.26 ± 35.97% of control, n = 7; post-HS 12-20 d: amplitude: 156.85 ± 6.25% of control, P < 0.01, n = 9; frequency: 186.66 ± 19.36% of control, n = 9) ( Fig. 1 B and C) . There were no significant changes in rise-time (10-90% of peak) and decay-time (90-10% of peak) of AMPAR sEPSCs at 1 h, 24 h, 48-72 h, 5-7 d, or 12-20 d post-HS compared with littermate controls (Fig. S1) . A similar dynamic, multiphasic pattern of change was detected for the miniature AMPAR EPSCs (mEPSCs) with early increases (1 h: amplitude 164.89 ± 7.83% of control, frequency 244.6 ± 35.07% of control, n = 9, P < 0.01) followed by a secondary decrease (48 h: amplitude 127.12 ± 6.09% of control, n = 9, P < 0.05, frequency 152.71 ± 23.22% of control, n = 9) and a return to enhanced activity 12-20 d after HS (12-20 d: amplitude 148.75 ± 6.91% of control, n = 9, P < 0.01, frequency 170.83 ± 16.09% of control, n = 9, P < 0.05). HS did not induce significant changes in the resting membrane potential, input resistance, action potential amplitude, duration, and threshold, or input-output function in CA1 neurons at different time points following HS (all P > 0.05, n = 8-12) (Figs. S2 and S3). Taken together, these data provide evidence for transient compensatory homeostatic modulation of AMPAR function during the subacute period in response to neural hyperexcitability induced by neonatal HS in CA1 pyramidal neurons. However, this compensation was incomplete and appeared to fail after 7-12 d post-HS, with a subsequent return of progressively increasing AMPA sEPSC/mEPSC amplitude (mEPSC/sEPSC: post-HS 48-72 h: n = 8-9, P < 0.05; sEPSC: post-HS 5-7 d: n = 7, P < 0.05) compared with post-HS 12-20 d (n = 9) without significant changes in AMPA sEPSC/mEPSC frequency.
PLK2 Expression Is Transiently Increased Following HS. Given the electrophysiological evidence for transient homeostatic regulation following HS, we next evaluated whether this period was associated with alterations in the expression level of mRNA and protein of PLK2, an important mediator of homeostatic plasticity in vitro (22, 23) . Real-time PCR quantification of PLK2 mRNA demonstrated significant increases at 1, 6, and 24 h after HS onset in hippocampus compared with littermate controls, peaking at post-HS 6 h (post-HS 1 h: 1.18 ± 0.03-fold increase; post-HS 6 h: 1.70 ± 0.18-fold of increase; and post-HS 24 h: 1.24 ± 0.04-fold increase, n = 4, P < 0.05) ( Fig. 2A) . Consistently, quantitative analysis of immunohistochemistry in hippocampus showed an overall significant increase in PLK2 protein expression in CA1 pyramidal neurons, prominent in both the cell bodies and the apical and basal dendrites at 48-72 h post-HS (cell body layer: 114.86 ± 3.69% of control, n = 6, P < 0.05; apical dendritic layer: 111.49 ± 3.22% of control, n = 6, P < 0.05) (Fig. 2B ). PLK2 mediates its compensatory functions in part through eliminating dendritic spines and attenuating AMPAR function through phosphorylation and degradation of the SPAR and PSD95 (22) (23) (24) . We thus examined the expression of SPAR and PSD95 at 48-72 h following HS at P10 using immunocytochemistry and found that SPAR expression was significantly reduced in hippocampal pyramidal cell bodies and apical dendrites of CA1 neurons (88.62 ± 3.06% of control in stratum pyramidale, n = 6, P < 0.05; 84.93 ± 3.08% of control in stratum radiatum, n = 6, P < 0.05) ( Fig. 2 C and D) . Similarly, PSD95 expression was significantly decreased in the apical dendritic layer (82.83 ± 5.99% of control, n = 8, P < 0.05) and in the cell body layer (90.45 ± 2.71% of control, n = 8, P < 0.05) (Fig. 2B) , consistent with previous studies, immunoblot results showing decreases in PSD95 expression in hippocampus following early-life seizures (25, 26) . These results suggest that early-life HS induced functional expression of PLK2 is occurring in parallel with the observed homeostatic compensation of HS-induced hyperexcitability.
PLK2 Activation Mediates Transient Homeostatic Down-Regulation of
Seizure-Induced Enhancement of AMPAR Function. To determine whether PLK2 was functionally related to the homeostatic changes in synaptic function, we tested whether PLK2 modulators in vivo could affect the subacute self-downward regulation of AMPAR function observed in slices following HS. The PLK1/2 kinase inhibitor BI-2536 (20 mg/kg, i.p.) at 30 min pre-HS was used to inhibit PLK2 (27, 28) and the proteasome-mediated degradation inhibitor MG132 (5 mg/kg) was chosen to potentiate the effects of PLK2 (23) (SI Materials and Methods). Compared with vehicle treatment pre-HS, at 24 and 48 h post-HS, slices from rats treated with BI-2536 showed significantly higher AMPAR sEPSC amplitude (24 h post-HS: 173.94 ± 11.04% of vehicletreated control, n = 7, P < 0.05; 48 h post-HS: 169.34 ± 8.77% of vehicle-treated control, n = 11, P < 0.05) (Fig. 3 A-C) and AMPAR sEPSC amplitude shows a dynamic downward regulation pattern following HS at P10, but it is significantly higher in all HS groups relative to that of normoxic controls (n = 7-12, *P < 0.01). (B2) AMPAR sEPSC frequency shows a dynamic downward regulation pattern following HS at P10 (n = 7-12; *P < 0.05). Error bars indicate SEM (C1-C3) Representative traces of AMPAR sEPSCs in CA1 neurons from post-HS 1h rat and P10 control (C1, Left), post-HS 7d rat and P17 control (C2, Left), and post-HS 12d rat and P22 control (C3, Left). Cumulative probability plots for AMPA sEPSC amplitude in post-HS rats and their littermate controls (C1-C3, Right) show a significant increase in AMPA sEPSC amplitude following HS (Kolmogorov-Smirnov test, *P < 0.01).
frequency (24 h post-HS: 331.26 ± 32.40% of vehicle-treated control, n = 7, P < 0.05; 48 h post-HS: 311.38 ± 25.87% of vehicletreated control, n = 11, P < 0.05) (Fig. 3 A, B, and D) . Thus, in vivo administration of BI-2536 prevented the dynamic down-regulation of enhanced AMPAR function seen subacutely after seizures. BI-2536 did not change rise-time (post-HS 24 h: 109.98 ± 14.35% of vehicle-treated control, n = 7; post-HS 48-72 h: 106.66 ± 9.19% of control, n = 11, all P > 0.05) and decay-time (post-HS 24 h: 99.36 ± 4.68% of vehicle-treated control, n = 7; post-HS 48-72 h: 103.04 ± 5.14% of control, n = 11, all P > 0.05).
In contrast, in vivo treatment with PLK2 breakdown inhibitor MG132 resulted in decreasing AMPAR sEPSC amplitude (95.73 ± 6.63% of vehicle-treated control, n = 5, P > 0.05) (Fig. 3 E-G) and frequency (150.03 ± 38.74% of vehicle-treated control, n = 5, P > 0.05) (Fig. 3 E, F , and H) at 48 h post-HS without significant changes in rise-time (105.26 ± 12.69% of vehicle-treated control, n = 5, P > 0.05) and decay-time (102.26 ± 7.51% of vehicle-treated control, n = 5, P > 0.05). Importantly, the effects of MG132 could be blocked by coadministration of BI-2536 (amplitude: 150.10 ± 10.76% of vehicle-treated control, n = 5, P < 0.05; frequency: 260.88 ± 53.71% of vehicle-treated control, n = 5, P < 0.05) (Fig. 3  E-H) . This modulation of AMPAR sEPSCs was not a result of nonspecific effects of BI-2536/MG132 on AMPAR function during development, as we did not observe any effects in normoxic rat pups (Fig. S4 A-C) . In addition, delayed in vivo administration of BI-2536 after 12 d postseizure (P22) did not affect AMPAR sEPSC amplitude and frequency (P > 0.05, n = 5) (Fig. S4 D-F) , consistent with the fact that PLK2 expression has already decreased at this time point. Taken together, these results indicate an important role of PLK2 in homeostatic compensation of AMPAR function following neonatal HS. However, unlike in vitro models (22) 
mTORC1 Pathway Activity Negatively Regulates PLK2-Mediated Homeostatic Plasticity Following Neonatal HS. mTOR is a key regulator of protein synthesis implicated in epileptogenesis in adult models of epilepsy (29) (30) (31) (32) as well as in our neonatal HS model (9) . As the mTOR pathway component TSC1 interacts with PLK2 (33), we hypothesized that HS-induced mTORC1 pathway activation would affect PLK2-mediated homeostatic regulation of AMPAR function, given that our prior studies have shown that mTORC1 pathway activation occurs in a similar temporal pattern following HS and that treatment with the mTOR inhibitor rapamycin blocks the development of later-life epilepsy (9) . Using the same rapamycin treatment paradigm in vivo, we confirmed the previously reported effect of rapamycin treatment on significantly decreasing the subacute enhancement of AMPAR function at 48 h post-HS (amplitude: 96.95 ± 5.03%of vehicle treated control rats, n = 6, P < 0.001; frequency: 112.31 ± 32.12% of vehicle treated control rats, n = 6, P > 0.05) (Fig. 4 D-F) . Consistently, immunocytochemical analysis showed significantly increased PLK2 expression in pyramidal neurons in rapamycin-treated HS rats (cell body layer: 122.43 ± 3.97% of vehicle-treated HS group, n = 6, P < 0.05; apical dendritic layer: 110.04 ± 2.42% of vehicle-treated HS group, n = 6, P < 0.05). In addition, there was a trend for a decrease in PSD95 expression in rapamycin-treated HS rats compared with vehicle-treated HS rats (cell body layer: 89.32 ± 5.35% of vehicle-treated HS group, n = 6, P = 0.06; apical dendritic layer: 85.27 ± 4.19% of vehicle-treated HS group, n = 6, P < (Fig. 4B) , indicating an inhibition of PLK2 expression and function by HS-induced mTORC1 pathway activation.
Given the apparent role of mTOR on seizure-induced PLK2 expression, we next tested whether PLK2 inhibition would occlude the protective effect of rapamycin following HS. Indeed, coadministration of the PLK2 inhibitor BI-2536 completely blocked the rapamycin-mediated attenuation of enhancement in AMPAR sEPSCs at 48 h post-HS (amplitude: 161.31 ± 3.88% of vehicle treated HS rats, n = 5, P < 0.001; frequency: 352.61 ± 46.65% of vehicle treated HS rats, n = 5, P < 0.01) (Fig. 4 C and  D) . Taken together, these data suggest HS-induced activation of mTORC1 contributed to the failure of PLK2 to mediate a full recovery of neuronal excitability. Importantly, treatment could not be attributed to alteration of the initial seizure stimulus, as neither the PLK2 inhibitor BI-2536 nor rapamycin treatment affected the severity of the initial HS at P10 [number of seizures per rat pup: vehicle: 8.08 ± 1.06, n = 13; BI-2536: 7.67 ± 1.37, n = 9; rapamycin: 7.57 ± 1.12, n = 7; P > 0.05) (Fig. 4A) ; average duration of seizures: vehicle: 15.75 ± 1.96 s, n = 8; BI-2536: 17.10 ± 2.38 s, n = 8; rapamycin: 15.24 ± 1.55s, n = 7, P > 0.05 (Fig. 4B)] .
Given the data that PLK2 modulators affected the early alterations in AMPAR function, and the fact early rapamycin treatment in this model can prevent long-term epilepsy, we next tested longterm effects of postseizure manipulations of PLK2 on AMPAR sEPSCs. Slices were prepared from rats at 12-20 d post-HS (P23-P30) treated with rapamycin, MG132, or vehicle 30 min before and 48 h after HS at P10. Compared with slices from vehicle-treated HS rats, rapamycin significantly decreased both the AMPAR sEPSC amplitude and frequency at P23-30 (amplitude: 67.33 ± 2.49% of vehicle-treated HS; frequency: 25.93 ± 2.15% of vehicle-treated HS, n = 7, P < 0.01) (Fig. 5 A-D) to a level comparable to vehicle-treated controls (amplitude: 104.23 ± 2.35% of control, n = 7, P > 0.05; frequency: 77.21 ± 6.38% of control, n = 7, P > 0.05). No effects of rapamycin on baseline AMPAR sEPSC amplitude and frequency were detected (amplitude: 108.23 ± 4.85% of vehicle-treated control, frequency: 80.33 ± 12.95% of vehicle-treated control, n = 5, P > 0.05) (Fig. 5 E-H) , making it unlikely these were a result of nonspecific effects on AMPAR function during development. Similarly, short-term application of the PLK2 potentiator MG132 further attenuated both the AMPAR sEPSC amplitude and frequency at P23-30 (amplitude: 70.12 ± 6.73% of vehicle-treated HS, n = 5, P < 0.05; frequency: 36.20 ± 10.04% of vehicle-treated HS, n = 5, P < 0.01). Taken together, these results support an important role of PLK2 regulated by mTORC1 pathway in early life HS-induced long-term enhancement of AMPAR function.
Discussion
Here we present the important evidence that early-life seizures are associated with a transient endogenous homeostatic down-regulation of enhanced AMPAR function mediated by seizure-induced PLK2 activation. We show that the PLK2-SPAR-PSD95 pathway, previously described in in vitro model systems, appears to be involved in the early endogenous antiepileptic compensation following neonatal seizures. We also reveal that seizure-induced mTORC1 pathway activation negatively regulates PLK2 function in the immature brain, which may in part underlie the failure of the homeostatic mechanisms to completely reverse the postseizure changes, resulting in epileptogenesis (8) . Furthermore, we show that manipulation of PLK2 function through inhibition of mTORC1 pathway with rapamycin rescues homeostatic compensation following HS, and in curtailment of mTOR-mediated progressive network excitability and later-life epilepsy, as shown in our prior work (9) . Hence, PLK2 mediated homeostatic compensation following HS may represent a therapeutic target for antiepileptogenesis.
PLK2 Activation Mediates Homeostatic Down-Regulation of Enhanced AMPAR Function Following Neonatal Seizures. Here we report a multiphasic pattern to AMPAR function following seizures at P10. There was an initial increase up to 12 h, then a secondary down-regulation of this enhancement, albeit not back to baseline levels seen in controls, followed by a third phase of a gradual reemergence of further increases in AMPAR sEPSCs in a seizure model that results in long-term epilepsy monitored using video-EEG recordings after several weeks (8) . Although a direct link between the enhancement of AMPAR function and later-life epilepsy is ideal, it would only be possible in future studies where homeostatic plasticity could be ascertained in vivo in the subacute period so that it could permit survival to later adulthood for correlation with the severity of later life epilepsy.
Induction of homeostatic plasticity can be highly dependent upon the preparation used (34) (35) (36) , and most studies have been carried out using neuronal cell/slice cultures (22, 37) . Little is known about physiological homeostatic responses and their molecular mechanisms induced by seizures in vivo, especially in the immature brain, which is characterized by rapid synaptogenesis and enhanced Hebbian plasticity and homeostatic plasticity (3, 7, 36) . Although GABA A receptor-mediated synaptic inhibition is persistently decreased following HS (38), here we show that the previously described initial enhancement of AMPAR function (6) was also transiently and dynamically down-regulated, but notably not to preseizure baseline levels. In contrast, the homeostatic plasticity in vitro, or synaptic scaling, evoked by prolonged disinhibition in cell/ slice cultures is manifested by a more complete and long-lasting suppression of mEPSC amplitude (22, 37) . Moreover, the postseizure transient homeostatic compensation is coincident with a seizure-free latent period starting from 2 d after the initial HS at P10 documented by video EEG (8) , suggesting that endogenous homeostatic regulation of excitation may account for the appearance of this brief seizure-free latent period.
The factors that regulate synaptic AMPAR function during homeostatic plasticity are still not fully elucidated (13, 14, 39) . Among the known mediators, PLK2 is believed to play a pivotal role in homeostatic synaptic downscaling (22) (23) (24) . In vitro neuronal cell and slice culture studies have shown an important role of PLK2 in homeostatic down-regulation of AMPAR function and intrinsic excitability in responses to chronic activity increases in hippocampal neurons (22) . Here, both PLK2 mRNA (over the course of several hours) and protein expression (over the course of a few days) were transiently increased following HS, consistent with reports on chemoconvulsant or electroconvulsive shock seizures in the adult rodent (40, 41) . In addition, we report here that treatment with a PLK2 inhibitor, BI-2536, at P10 attenuated the seizure-induced homeostatic drop in AMPAR function. Conversely, potentiating PLK2 function with MG132 led to full recovery of AMPAR function to control levels. Thus, our data suggest that PLK2-mediated dampening of synaptic strength is present as an endogenous compensation toward stabilizing neuronal activity following HS, and antiepileptogenic therapies could be developed to enhance PLK2 function.
In the immature brain, AMPARs are highly Ca
2+
-permeable and can mediate long-lasting increases in AMPAR function and synaptic strength (3), in part mediated by synaptic receptor trafficking (6) . The small GTPases Ras and Rap are molecular signaling switches critically involved in modulating synaptic AMPAR trafficking during long-term potentiation and longterm depression, and many forms of memory formation (24, 42) . Importantly, PLK2 has been shown to directly phosphorylate both Ras and Rap at synapses (24, 43) . Indeed, HS-induced increases in PLK2 expression led to degradation of SPAR and associated PSD95 in hippocampal CA1 neurons, which may be because of degradation downstream of Ras/Rap signaling (23, 44) . Future studies may warrant examining the role of Ras/Rap signaling in PLK2-mediated homeostatic compensation following early life epilepsy. (45, 46) . More importantly, at this time point, the appearance of spontaneous seizures (epilepsy) has been demonstrated in our recent study using video-EEG recordings (8) . The failure of homeostatic regulation by HS-induced PLK2 activation appears to be at least in part because of mTORC1 pathway activation. Neonatal HS-induced mTORC1 activation (9) inhibits the transient PLK2 activation. In addition, mTORC1 inhibition by rapamycin enhances HS-induced PLK2 expression, which in turn attenuates HS-induced both subacute and long-term enhancement of AMPAR function. These changes are in the context of our previous observation showing that treatment with the mTORC1 inhibitor rapamycin attenuated HS-induced later life spontaneous seizures as well as autism-like behaviors in the identical HS model (9) . The mTORC1 signaling pathway has been shown to be critical in regulating protein translation and synaptic plasticity (47, 48) . mTORC1 activity was highest in hippocampus and cortex during early development (9) . Seizures in both immature and adult brains can induce early increases in mTORC1 expression and function (9, 29, 30) . Although overactivation of mTORC1 signaling has been thought to promote the initiation of protein translation (47, 49, 50) , there are pathways that are likely compensatory whereby the translational repressor eukaryotic elongation factor 2 is phosphorylated by mTOR activation, and can down-regulate protein translation up to 50% (51, 52) . Thus, it is possible that neonatal HS-induced mTORC1 activation alters PLK2 translation, which would be supported by our findings that mTORC1 inhibition by rapamycin increases HS-induced PLK2 protein expression. On the other hand, PLK2 itself can regulate the mTOR pathway, and has been shown to affect mTOR signaling through PLK2-TSC1 interaction during hypoxia in lung tumor cells (33) . Blockade of PLK2 function attenuates rapamycin mediated rescue of HSinduced network hyperexcitability (9) , suggesting an important interaction and role of PLK2 signaling in mTORC1-mediated epileptogenesis.
In summary, the present study shows that, similar to in vitro (22, 24) , PLK2-mediated homeostatic plasticity mediates antiepileptic responses following in vivo neonatal HS. The shortlived compensation appears to be at least in part because of HSinduced mTORC1 activation that negatively regulates PLK2 function and impairs homeostatic regulation of enhanced synaptic strength. Thus, promoting homeostatic compensation with PLK2 potentiators or mTOR inhibitors may represent a unique mechanism for neonatal seizure-induced long-term neuronal network hyperexcitability and provide a unique target to prevent long-term consequences of early life seizures.
Materials and Methods.
Animals. HS were induced in P10 male Long Evans pups (53) . Although associated with potential clinical translation limitations, a pretreatment (30 
